PBPrafulla Bhagat

Prafulla Bhagat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prafulla Bhagat has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures S1-S2 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Supplemental Figure 1. Overall Survival Responders vs Non-Responders Supplemental Figure 2. Overall Survival Among Groups

  • Open Access

    Supplementary Tables S1-S5 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Supplemental Table 1. MDS International Working Group response criteria for hematologic improvement Supplemental Table 2. Differences in Baseline Patient Characteristics Supplemental Table 3. Responses by Cytogenetics Supplemental Table 4. Responses by Mutation Supplemental Table 5. Study Representativeness Table

  • Open Access

    Data from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Purpose:Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalidomide (LEN) in preclinical studies. We hypothesized ELT would reduce the incidence of thrombocytopenia in MDS.Patients and Methods:We conducted a Phase II multicenter trial of ELT and LEN in adult patients with low- or intermediate-1–risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia (NCT01772420). Thrombocytopenic patients were started on ELT and subsequently treated with LEN after platelets were increased. Patients without thrombocytopenia were started on LEN monotherapy and treated with ELT if they became thrombocytopenic.Results:Fifty-two patients were enrolled; mean age was 71 years (range 34–93). Overall response rate (ORR) in the intention-to-treat population was 35% (18/52). ELT monotherapy led to ORR of 33.3% (7/21), 29% achieving hematologic improvement (HI)-Platelets, and 24% bilineage responses. LEN monotherapy had 38% ORR (6/16) with all responders achieving HI-Erythroid. Fifteen patients received both ELT and LEN with ORR of 33.3%, 20% achieved HI-Erythroid, and 20% HI-Platelets with 13% bilineage responses. Median duration of response was 40 weeks for ELT (range 8–ongoing), 41 weeks (25–ongoing) for LEN, and 88 weeks (8.3–ongoing) for ELT/LEN. Non-hematologic grade 3–4 treatment-related adverse events were infrequent. Among patients on ELT, 2 had major bleeding events, 1 had a reversible increase in peripheral blasts, and 1 developed marrow fibrosis after 6 years on ELT.Conclusions:ELT and LEN are well tolerated and effective in achieving hematologic improvement in patients with low-/intermediate-risk MDS.

  • Open Access

    Supplementary Figures S1-S2 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Supplemental Figure 1. Overall Survival Responders vs Non-Responders Supplemental Figure 2. Overall Survival Among Groups

  • Open Access

    Supplementary Tables S1-S5 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Supplemental Table 1. MDS International Working Group response criteria for hematologic improvement Supplemental Table 2. Differences in Baseline Patient Characteristics Supplemental Table 3. Responses by Cytogenetics Supplemental Table 4. Responses by Mutation Supplemental Table 5. Study Representativeness Table

  • Open Access

    Supplementary Tables S1-S5 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Supplemental Table 1. MDS International Working Group response criteria for hematologic improvement Supplemental Table 2. Differences in Baseline Patient Characteristics Supplemental Table 3. Responses by Cytogenetics Supplemental Table 4. Responses by Mutation Supplemental Table 5. Study Representativeness Table

  • Open Access

    Supplementary Figures S1-S2 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Supplemental Figure 1. Overall Survival Responders vs Non-Responders Supplemental Figure 2. Overall Survival Among Groups

  • Open Access

    Data from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Purpose:Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalidomide (LEN) in preclinical studies. We hypothesized ELT would reduce the incidence of thrombocytopenia in MDS.Patients and Methods:We conducted a Phase II multicenter trial of ELT and LEN in adult patients with low- or intermediate-1–risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia (NCT01772420). Thrombocytopenic patients were started on ELT and subsequently treated with LEN after platelets were increased. Patients without thrombocytopenia were started on LEN monotherapy and treated with ELT if they became thrombocytopenic.Results:Fifty-two patients were enrolled; mean age was 71 years (range 34–93). Overall response rate (ORR) in the intention-to-treat population was 35% (18/52). ELT monotherapy led to ORR of 33.3% (7/21), 29% achieving hematologic improvement (HI)-Platelets, and 24% bilineage responses. LEN monotherapy had 38% ORR (6/16) with all responders achieving HI-Erythroid. Fifteen patients received both ELT and LEN with ORR of 33.3%, 20% achieved HI-Erythroid, and 20% HI-Platelets with 13% bilineage responses. Median duration of response was 40 weeks for ELT (range 8–ongoing), 41 weeks (25–ongoing) for LEN, and 88 weeks (8.3–ongoing) for ELT/LEN. Non-hematologic grade 3–4 treatment-related adverse events were infrequent. Among patients on ELT, 2 had major bleeding events, 1 had a reversible increase in peripheral blasts, and 1 developed marrow fibrosis after 6 years on ELT.Conclusions:ELT and LEN are well tolerated and effective in achieving hematologic improvement in patients with low-/intermediate-risk MDS.

  • Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

    by Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, et al.

    Purpose: Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalidomide (LEN) in preclinical studies. We hypothesized ELT would reduce the incidence of thrombocytopenia in MDS. Patients and Methods: We conducted a Phase II multicenter trial of ELT and LEN in adult patients with low- or intermediate-1–risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia (NCT01772420). Thrombocytopenic patients were started on ELT and subsequently treated with LEN after platelets were increased. Patients without thrombocytopenia were started on LEN monotherapy and treated with ELT if they became thrombocytopenic. Results: Fifty-two patients were enrolled; mean age was 71 years (range 34–93). Overall response rate (ORR) in the intention-to-treat population was 35% (18/52). ELT monotherapy led to ORR of 33.3% (7/21), 29% achieving hematologic improvement (HI)-Platelets, and 24% bilineage responses. LEN monotherapy had 38% ORR (6/16) with all responders achieving HI-Erythroid. Fifteen patients received both ELT and LEN with ORR of 33.3%, 20% achieved HI-Erythroid, and 20% HI-Platelets with 13% bilineage responses. Median duration of response was 40 weeks for ELT (range 8–ongoing), 41 weeks (25–ongoing) for LEN, and 88 weeks (8.3–ongoing) for ELT/LEN. Non-hematologic grade 3–4 treatment-related adverse events were infrequent. Among patients on ELT, 2 had major bleeding events, 1 had a reversible increase in peripheral blasts, and 1 developed marrow fibrosis after 6 years on ELT. Conclusions: ELT and LEN are well tolerated and effective in achieving hematologic improvement in patients with low-/intermediate-risk MDS.


  • Open Access

    Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation

    by Tushar D. Bhagat, Si Chen, Matthias Bartenstein, A. Trevor Barlowe, Dagny Von Ahrens, Gaurav S. Choudhary, Patrick Tivnan, Elianna Amin, A. Mario Marcondes, Mathijs A. Sanders, et al.

    The bone marrow microenvironment influences malignant hematopoiesis, but how it promotes leukemogenesis has not been elucidated. In addition, the role of the bone marrow stroma in regulating clinical responses to DNA methyltransferase inhibitors (DNMTi) is also poorly understood. In this study, we conducted a DNA methylome analysis of bone marrow–derived stromal cells from myelodysplastic syndrome (MDS) patients and observed widespread aberrant cytosine hypermethylation occurring preferentially outside CpG islands. Stroma derived from 5-azacytidine–treated patients lacked aberrant methylation and DNMTi treatment of primary MDS stroma enhanced its ability to support erythroid differentiation. An integrative expression analysis revealed that the WNT pathway antagonist FRZB was aberrantly hypermethylated and underexpressed in MDS stroma. This result was confirmed in an independent set of sorted, primary MDS-derived mesenchymal cells. We documented a WNT/β-catenin activation signature in CD34+ cells from advanced cases of MDS, where it associated with adverse prognosis. Constitutive activation of β-catenin in hematopoietic cells yielded lethal myeloid disease in a NUP98–HOXD13 mouse model of MDS, confirming its role in disease progression. Our results define novel epigenetic changes in the bone marrow microenvironment, which lead to β-catenin activation and disease progression of MDS. Cancer Res; 77(18); 4846–57. ©2017 AACR.